VRTX - VERTEX PHARMACEUTICALS INC / MA
488.29
2.570 0.526%
Share volume: 1,198,359
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.05%
PREVIOUS CLOSE
CHG
CHG%
$485.72
2.57
0.01%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-02-2023 | 08-02-2023 | 11-07-2023 | 02-15-2024 | 05-07-2024 | 08-02-2024 | 11-05-2024 | 02-13-2025 | |
| Assets | |||||||||
| Total Assets | 18.974 B | 20.349 B | 21.726 B | 22.730 B | 23.917 B | 20.132 B | 22.240 B | 22.533 B | |
| Current Assets | 12.966 B | 13.873 B | 14.696 B | 14.144 B | 13.289 B | 8.942 B | 9.804 B | 9.596 B | |
| Inventories | 535.100 M | 603.500 M | 688.700 M | 738.800 M | 813.100 M | 914.600 M | 1.080 B | 1.205 B | |
| Other Current Assets | 468.700 M | 476.900 M | 540.200 M | 623.700 M | 511.100 M | 575.400 M | 0.000 | 0.000 | |
| Short Term Investments | 468.700 M | 476.900 M | 540.200 M | 623.700 M | 511.100 M | 575.400 M | 1.285 B | 1.546 B | |
| Total Receivables | 1.548 B | 1.556 B | 1.539 B | 1.563 B | 1.793 B | 1.656 B | 0.000 | 0.000 | |
| Current Cash | 10.414 B | 11.236 B | 11.928 B | 11.218 B | 10.171 B | 5.796 B | 5.239 B | 4.570 B | |
| Total Non-current Assets | 6.009 B | 6.476 B | 7.030 B | 8.586 B | 10.629 B | 11.191 B | 4.704 B | 5.108 B | |
| Property Plant Equipment | 1.112 B | 1.122 B | 1.124 B | 1.159 B | 1.173 B | 1.201 B | 1.118 B | 1.228 B | |
| Other Assets | 328.900 M | 344.100 M | 376.600 M | 796.700 M | 801.400 M | 915.600 M | 11.318 B | 11.709 B | |
| Intangible Assets | 603.600 M | 603.600 M | 603.600 M | 839.900 M | 834.900 M | 837.500 M | 0.000 | 0.000 | |
| Goodwill | 1.088 B | 1.088 B | 1.088 B | 1.088 B | 1.088 B | 1.088 B | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 18.974 B | 20.349 B | 21.726 B | 22.730 B | 23.917 B | 20.132 B | 22.240 B | 22.533 B | |
| Total liabilities | 4.542 B | 4.879 B | 5.213 B | 5.150 B | 5.371 B | 5.357 B | 6.609 B | 6.124 B | |
| Total current liabilities | 3.026 B | 3.352 B | 3.599 B | 3.547 B | 3.796 B | 3.547 B | 3.973 B | 3.565 B | |
| Accounts Payable | 323.200 M | 363.000 M | 375.900 M | 364.900 M | 351.400 M | 327.900 M | 395.800 M | 413.000 M | |
| Other liabilities | 726.500 M | 759.300 M | 869.300 M | 877.700 M | 853.600 M | 876.800 M | 2.636 B | 2.559 B | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 50.600 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 417.600 M | 404.100 M | 390.300 M | 376.100 M | 361.500 M | 346.600 M | 0.000 | 0.000 | |
| Other liabilities | 726.500 M | 759.300 M | 869.300 M | 877.700 M | 853.600 M | 876.800 M | 2.636 B | 2.559 B | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 14.432 B | 15.470 B | 16.513 B | 17.580 B | 18.547 B | 14.775 B | 15.631 B | 16.410 B | |
| Common stock | 257.400 M | 257.700 M | 258.000 M | 257.700 M | 258.200 M | 258.100 M | 6.908 B | 6.675 B | |
| Retained earnings | 7.223 B | 8.138 B | 9.174 B | 10.142 B | 11.242 B | 7.648 B | 8.694 B | 9.607 B |